Binah Capital Group, Inc. BCG
1.64 USD -0.17 (-9.39%)
Regular-session close
1.61 -0.03 -1.83%
After hours · Nov 20, 4:00 PM ET
1.50 Day range 1.87
0.991 52-week range 3.11
- YTD
- -43.06%
- 1 year
- -29.61%
News
benzinga.com 12 Financials Stocks Moving In Friday's Pre-Market Session Gainers CaliberCos (NASDAQ:CWD) stock moved upwards by 11.1% to $0.41 during Friday's pre-market session. The market value of their outstanding shares is at $4.1 million. Yiren Digital (NYSE:YRD)…benzinga.com Binah Capital Group Q3 EPS $0.13 Up From $0.08 YoY, Sales $50.561M Beat $46.850M Estimate Binah Capital Group (NASDAQ:BCG) reported quarterly earnings of $0.13 per share. This is a 62.5 percent increase over earnings of $0.08 per share from the same period last year. The company reported…
globenewswire.com Binah Capital Group Reports Results for Third Quarter of 2026 - Assets Under Management (“AuM”) Increased 5.0% Year-over-Year to $31.4 Billion -
businesswire.com enGene to Initiate a BLA Submission for Detalimogene by Year End and Reports New Data from LEGEND Trial Pivotal Cohort 1 in BCG-Unresponsive NMIBC BOSTON & MONTREAL--(BUSINESS WIRE)--enGene Therapeutics Inc. (Nasdaq: ENGN, “enGene” or the “Company”), a clinical-stage, non-viral genetic medicines company, today announced updated results from the…
gurufocus.com IMFINZI® (durvalumab) plus tarlatamab-dlle reduced the risk of death by 58% in 1st-line extensive-stage small cell lung cancer in the DeLLphi-305 Phase III trial Landmark results from the DeLLphi-305 Phase III trial showed IMFINZIÂ (durvalumab) plus Amgen's tarlatamab-dlle demonstrated a statistically significant and hi
gurufocus.com Perioperative IMFINZI® (durvalumab) plus neoadjuvant enfortumab vedotin reduced risk of recurrence by 49% and risk of death by 42% in muscle-invasive bladder cancer Positive results from the VOLGA Phase III trial showed perioperative treatment with AstraZeneca's IMFINZIÂ (durvalumab) in combination with neoadjuvant enfortu
gurufocus.com Merck and Moderna Will Present Results From Landmark Phase 3 INTerpath-001 Trial for Intismeran Autogene Plus KEYTRUDA® (pembrolizumab) at ESMO 2026 Presidential Symposium Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and Moderna, Inc. (NASDAQ: MRNA) today announced detailed positive recurrence-free surv
businesswire.com FDA Expands ANKTIVA® Approval for BCG-Unresponsive Non-Muscle-Invasive Bladder Cancer to Cover Both Papillary and CIS Disease CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), a commercial-stage immunotherapy company, today announced that the U.S. Food and Drug Administration (FDA) has expanded the…
defenseworld.net Binah Capital Group, Inc. (NASDAQ:BCG) Stock Short Interest Report for September Binah Capital Group, Inc. (NASDAQ: BCG - Get Free Report) was the recipient of a significant decline in short interest in September. As of September 30th, there was short interest totaling 2,413…
defenseworld.net Head-To-Head Comparison: Binah Capital Group (NASDAQ:BCG) versus Hennessy Advisors (NASDAQ:HNNA) Binah Capital Group (NASDAQ: BCG - Get Free Report) and Hennessy Advisors (NASDAQ: HNNA - Get Free Report) are both small-cap finance companies, but which is the superior business? We will compare…
defenseworld.net Binah Capital Group (NASDAQ:BCG) and PennantPark Investment (NASDAQ:PNNT) Financial Survey PennantPark Investment (NASDAQ: PNNT - Get Free Report) and Binah Capital Group (NASDAQ: BCG - Get Free Report) are both small-cap finance companies, but which is the superior investment? We will…
gurufocus.com Merck Receives Positive EU CHMP Opinion for KEYTRUDA® (pembrolizumab) Plus Padcev® (enfortumab vedotin-ejfv) as Perioperative Treatment for Adults With Resectable Muscle-Invasive Bladder Cancer (MIBC) Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the European Medicines Agency's Committee for Medicinal Products for Hu
businesswire.com New ABB and BCG Report Highlights Growing Role of Direct Current Technologies in Future Power Systems ZURICH--(BUSINESS WIRE)--ABB today published a new report, The Strategic Case for Hybrid AC/DC Power: Shaping the Transition to the Next Electrical Architecture, developed in collaboration with…
gurufocus.com New ABB and BCG report highlights growing role of direct current technologies in future power systems New ABB and BCG report highlights growing role of direct current technologies in future power systems PR Newswire
globenewswire.com Binah Capital Group Reports Results for Second Quarter of 2026 - Assets Under Management (“AuM”) Increased 13.4% Year-over-Year to $31.6 Billion - - Increased Net Income to $0.3 Million from a net loss of $(0.7) million in the Prior Year Period - - Increased…
globenewswire.com Binah Capital Group to Participate in Sidoti Micro-Cap Virtual Conference August 19-20 NEW YORK, Aug. 12, 2026 (GLOBE NEWSWIRE) -- Binah Capital Group, Inc. (“Binah”, “Binah Capital” or the “Company”) (NASDAQ: BCG; BCGWW), a leading financial services enterprise that owns and operates…
youtube.com BCG CEO: AI adoption now as high on CEOs' agenda as profits Christoph Schweizer, CEO of Boston Consulting Group (BCG), tells CNBC's Squawk Box Europe that AI adoption is now as much on the minds of global CEOs as sales and profits, as businesses begin to…
gurufocus.com enGene Reports Second Quarter 2026 Financial Results and Provides Business Update enGene Therapeutics Inc. (Nasdaq: ENGN, âenGeneâ or the âCompanyâ), a clinical-stage, non-viral genetic medicines company today announced its financial
businesswire.com 81% of Enterprises Report AI Initiatives Delayed, Scaled Back, or Abandoned Due to Data Permission and Governance Gaps, Finds Transcend Research SAN FRANCISCO--(BUSINESS WIRE)--Transcend, the autonomous "can I use this data?" platform that powers every data decision to scale customer growth, released The 2026 State of Customer Data in the…
gurufocus.com FDA Grants Breakthrough Therapy Designation for Calderasib (MK-1084), an Investigational KRAS G12C Inhibitor, for Certain Patients with Newly Diagnosed Metastatic KRAS G12C-Mutant Non-Small Cell Lung Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced that calderasib (MK-1084), an investigational oral specific KRAS G12C inhibi
gurufocus.com IMFINZI® (durvalumab) approved in the US in first and only immunotherapy combination for patients with BCG-naïve, high-risk non-muscle-invasive bladder cancer AstraZeneca's IMFINZIÂ (durvalumab) in combination with Bacillus Calmette-GuÃrin (BCG) induction and maintenance therapy has been approved in the US for the
businesswire.com IMFINZI® (durvalumab) approved in the US in first and only immunotherapy combination for patients with BCG-naïve, high-risk non-muscle-invasive bladder cancer WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca's IMFINZI® (durvalumab) in combination with Bacillus Calmette-Guérin (BCG) induction and maintenance therapy has been approved in the US for the…
